Sigyn Therapeutics Inc.

SIGY

⚠ Showing the latest available close (Nov 3, 2026, 2 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.

Sigyn Therapeutics, Inc. ( Sigyn , the Company we, us, or our ) develops medical devices to treat cancer and infectious disease disorders. We believe our lineup of therapeutic candidates is among the most expansive in the field of extracorporeal blood purification.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$45K

EPS-$1.93

P/E-0.01

P/FCF-0.05

EV/EBITDA-2.41

FCF Yield–

Div. Yield–

Net Debt/FCF-4.8x

Sigyn Therapeutics Inc. intrinsic value

52-Week Range

$0.02$0.08

Profitability & Returns

TTM as of 2025-09 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$3M

▲ +19.4% YoY

Op. Margin

–

ROIC

-48.01%

▼ -12.3pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$936K

▲ +36.9% YoY

Op. Cash Flow (TTM)

-$936K

▲ +36.9% YoY

Net Debt

$4M

Cash & Equiv.

$86K

3Y CAGR: +69.9%

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with SIGY

CompareIntrinsic value

MBOTMicrobot Medical Inc.

$1.14+4.59%25

PAVMPAVmed Inc.

$1.66-8.79%25

RDGLVivos Inc.

$0.04-1.64%40

FOFAFamily Office of America Inc.

$0.78+0.00%16

LYRALyra Therapeutics Inc.

$0.19+0.00%0

CODXCo-Diagnostics Inc.

$0.36-5.00%10

EMEDElectromedical Technologies Inc.

$0.00+0.00%26

HRGNHarvard Apparatus Regenerative Technology Inc.

$2.30+0.00%10

Sigyn Therapeutics (SIGY) in three numbers

Quality score: 30/100; Best check: revenue growth, 69.9%. Weakest: return on capital, -48.0%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -0.01; Negative: a loss over the last twelve months. Price to free cash flow -0.05.; Financials

Questions about Sigyn Therapeutics

Is Sigyn Therapeutics a high-quality business?

Sigyn Therapeutics scores 30 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 69.9%, and its weakest is return on capital at -48.0%. The Quality tab shows every check against its target.

Does Sigyn Therapeutics (SIGY) pay a dividend?

No. Sigyn Therapeutics (SIGY) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 14 Nov 2025 (period ending 30 Sept 2025), SEC. Price: last close 3 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in SIGY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SIGY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.